Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q32 BioFRA:DB0 -3.69%25 3-1 Month Momentum % is 146.20% as of Aug. 21, 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Q32 Bio ranks better than 99.28% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), Q32 Bio's 3-1 Month Momentum % is 146.20%.
The industry rank for Q32 Bio's 3-1 Month Momentum % or its related term are showing as below:
FRA:DB0's 3-1 Month Momentum % is ranked better than 99.28% of 1386
companies
in the Biotechnology industry
Industry Median: -7.01
vs FRA:DB0: 146.20
Q32 Bio (FRA:DB0) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Q32 Bio 3-1 Month Momentum % Related Terms
FRA:DB0 vs KYTX, PRTA, CABA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Q32 Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Q32 Bio's 3-1 Month Momentum % falls into.
Q32 Bio (FRA:DB0) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio (FRA:DB0) has a 3-1 Month Momentum % of 146.20% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #10 out of 1386 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Q32 Bio's 3-1 Month Momentum % too high?
Q32 Bio's current 3-1 Month Momentum % is 146.20%. Based on the distribution chart, Q32 Bio ranks #10 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's 3-1 Month Momentum % compare to KYTX and PRTA?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #10 out of 1386 companies for 3-1 Month Momentum %. This places Q32 Bio in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Q32 Bio and its competitors. Q32 Bio's current 3-1 Month Momentum % is 146.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current 3-1 Month Momentum % of 146.20%. The current 3-1 Month Momentum % is 146.20%. Q32 Bio's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current 3-1 Month Momentum % is 146.20% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
25GF Score
Get the complete analysis for FRA:DB0
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
